Target dose, effective dose, and the distance between them
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 31 of 31 of this archive, newest first.
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
The practice is near-universal, clinically sensible, and supported by observational data rather than randomised comparison. We say which is which.
The evidence base is thin and the document says so, which is to its credit.
The evidence base is thin and the document says so, which is to its credit.
The evidence base is thin and the document says so, which is to its credit.
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
A unit is a volume. A dose is a mass. The bridge between them is concentration, and concentration is a number somebody has to calculate.
The features that should prompt urgent assessment, stated once and plainly.